| Literature DB >> 32283702 |
Gustavo A Molina1, Alberto Elizalde-Mata1, Ángel R Hernández-Martínez2, Gerardo Fonseca2, Martha Cruz Soto3, Ángel Luis Rodríguez-Morales2, Miriam Estevez2.
Abstract
In this study, new polyurethanes (Entities:
Keywords: biomarker; breast cancer; drug delivery; inulin; polysaccharide-based polyurethane
Year: 2020 PMID: 32283702 PMCID: PMC7240393 DOI: 10.3390/polym12040865
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Molar ratios between polyol:isocyanate precursor and the amount of precursor used for synthesized inulin-based polyurethane (PU–INU).
| Sample | OH:NCO | Per Mole of OH | HDI [mg] | INU [mg] | PCL-diol [mg] |
|---|---|---|---|---|---|
| INU33 | 1:3.4 | 1:2 | 183.969 | 457.88 | 437.67 |
| INU50 | 1:1 | 915.57 | 218.83 | ||
| INU66 | 2:1 | 686.81 | 328.26 |
Figure 1Fourier transform infrared spectroscopy (FT-IR) spectra of (a) INU and polycaprolactone diol (PCL-diol) as polyol precursors and (b) PU–INU base materials and their adsorption characteristic bands. Nomenclature corresponds to: ν = stretching, δ = bending, and ω = wagging.
Figure 2Raman spectra from PU–INU based materials and their adsorption characteristic bands.
Figure 3(a) 1H and (b) 13C spectrum of INU33 in dimethyl sulfoxide (DMSO)-d6 at 500 and 125 MHz, respectively. (c) Schematic representation of the suggested structure for PU–INU50 polyurethane. In red color are marked fructans from inulin where m ≈ 36, hexamethylene diisocyanate (HDI) moiety and the urethane linkage are marked in moss-green color, PCL-diol contributions are marked in navy-blue color, HDI or putrescine chain extensor of PU–INU50 are marked in olive-green color and in blue color are marked the letter that corresponds to the chemical moieties observed in NMR.
Figure 4(a) Thermogravimetric analysis of polyol precursors (inulin and PCL) and synthesized PU–INU. Thermogravimetric analysis and its derivative (DTG) of (b) PU–INU33, (c) PU–INU50, and (d) PU–INU66.
Temperatures related to the different degradation step process in the PU–INU based materials.
| Sample | Tmax1 [°C] | Tmax-new [°C] | Tmax2 [°C] | WR [%] |
|---|---|---|---|---|
| PU–INU33 | 319.0 | --- | 425.4 | 20.23 |
| PU–INU50 | 276.9 | 328.2 | 425.8 | 24.52 |
| PU–INU66 | 282.7 | 390.2 | 425.5 | 24.02 |
Mechanical properties values obtained of the synthesized PU–INU.
| Sample | E 1 [MPa] | YS 2 [MPa] | TS 3 [MPa] | SA 4 [%] | SA-PL 5 [mm/mm] | S-PL 6 [MPa] |
|---|---|---|---|---|---|---|
| PU–INU33 | 20.88 | 0.24 | 0.97 | 18.26 | 0.16 | 0.03 |
| PU–INU50 | 50.31 | 0.28 | 0.84 | 32.81 | 0.25 | 0.01 |
| PU–INU66 | 3.18 | 0.03 | 0.74 | 96.30 | 0.04 | 0.07 |
1 Young modulus, 2 Yield Stress, 3 Tensile Strength, 4 Strain, 5 Strain Proportionality Limit, 6 Stress Proportionally Limit.
Figure 5Mechanical behavior of the synthesized PU–INU. (a) Mechanical properties until maximum tensile strength was reached, (b) mechanical properties in the elastic region, and (c) example of the required specimen according to ASTM-D638-03 standard and the actual film.
Figure 6Swelling properties of the PU–INU’s: (a) swelling profile against time, (b) maximum swelling ratio against mol % of inulin per mol of polyol, (c) swelling ratio at different temperatures, and (d) swelling ratio at different pH.
Figure 7Degradability rate under specific pH and temperature conditions (7.4 at 37 °C) of the different PU–INU synthesized.
Results of degradation rate in physiological conditions (pH 7.4 and 37 °C) and weight loss percentage after an elapsed time of two months of experiments.
| Sample |
| Weight Loss (%) | |
|---|---|---|---|
| PU–INU33 | 0.1028 | 0.9795 | 34.43 |
| PU–INU50 | 0.077 | 0.9671 | 52.47 |
| PU–INU66 | 0.1216 | 0.9411 | 93.85 |
Figure 8Application of PU–INU’s as drug delivery system of doxorubicin hydrochloride (DOXO). (a) DOXO UV–Vis spectra at 1 mg·mL−1, (b) DOXO calibration curve with a linear fit of R2 > 0.99, (c) sorption capacity (q, mg·g−1) of synthesized PU–INU, and (d) drug released relative to drug loading concentration of PU–INU.
Mathematical model correlates coefficients and release exponents for PU–INU.
| Model | Parameter | Sample | ||
|---|---|---|---|---|
| PU–INU33 | PU–INU50 | PU–INU66 | ||
| Zero Order |
| 0.9198 | 0.8388 | 0.3524 |
|
| 0.0009 | 0.0081 | 0.0499 | |
| First Order |
| 0.2741 | 0.7812 | −0.0136 |
|
| 0.0003 | 1.0491 | 0.0003 | |
| Higuchi |
| 0.9206 | 0.9353 | 0.4542 |
|
| 0.0665 | 0.5705 | 2.3797 | |
| Korsmeyer-Peppas |
| 0.4476 | 0.9846 | 0.2067 |
|
| 0.0088 | 1.1073 | 5.2722 | |
|
| 0.7600 | 0.3192 | 0.4371 | |
Figure 9Elemental mapping of the Fe3O4 iron oxide nanoparticles (IONPs) on PU–INU50. (a) Element (Fe + O + C) overlay distribution on the polyurethane, (b) complete electron dispersive spectroscopy (EDS) spectra of all elements distribution, (c) scanning electron microscopy (SEM) image and (d–f) element mapping of Fe (red), O (green), and C (blue).
Figure 10Images of radiopaque validation of PU–INU50. (a) X-Ray imaging and (b) grayscale histogram of the prototype marker, (c) X-Ray imaging, and (d) histogram of the prototype marker inside model tissue.
Grayscale data from radiopaque analysis done to the composite X-Ray images.
| Minimum (bit) | Maximum (bit) | Average (bit) | Relative Radiopacity against Background (%) | |
|---|---|---|---|---|
| Background | 0 | 19 | 10 | 0 |
| Composite | 42 | 250 | 146 | 93.20 |
| Background | 0 | 123 | 62 | 0 |
| Composite | 31 | 249 | 140 | 55.72 |
| Soft Tissue | 11 | 195 | 103 | 39.81 |